Rokotetutkimuskeskus Finvac Oy
- Address
- lock Available on a paid plan
Respiratory and Viral Vaccine Research
At Rokotetutkimuskeskus Finvac Oy in Tampere, a major share of the work focuses on respiratory tract diseases and virus diseases, especially influenza, respiratory syncytial virus (RSV), COVID-19, and human metapneumovirus. These studies generally aim to test new vaccines and antiviral approaches, while also measuring immune responses and protection in different age groups.
- Influenza prevention and vaccine effectiveness in adults and older adults
- RSV and related respiratory virus protection in infants, children, and seniors
- COVID-19 treatment evaluation in people at higher risk of severe illness
The site’s vaccine-focused expertise supports research on both seasonal and emerging viral threats, with an emphasis on safety, immune response, and real-world protection.
Bacterial Infection and Meningococcal Vaccine Studies
This research site also conducts extensive work in bacterial infections, particularly meningococcal disease, pneumococcal disease, and group B streptococcus (GBS). The trials are designed to evaluate new or improved vaccines, compare immune responses, and strengthen prevention strategies for serious invasive infections.
- Meningococcal immunization in infants, toddlers, children, and adolescents
- Pneumococcal vaccination research for protection against invasive disease
- Maternal vaccination studies aimed at preventing GBS disease in newborns
These programs reflect a strong focus on protecting vulnerable populations from severe bacterial illness through better vaccine-induced immunity.
Older Adult Immunization and Long-Term Protection
Several trials at the Tampere Vaccine Clinic address immune system diseases and age-related vulnerability by studying vaccines in older adults. Research includes herpes zoster, high-dose influenza vaccination, and RSV prevention, with the goal of improving protection where immune responses may be weaker.
- Vaccines for shingles and other preventable infections in older adults
- Comparisons of immune response and protection across vaccine options
- Studies of durability and persistence of vaccine-induced immunity
These trials help clarify how well vaccines work over time and whether they can reduce illness burden in aging populations.
Pediatric and Maternal Prevention Research
The site also contributes to research in immune system processes through studies involving pregnant women, infants, and young children. Trials in this area focus on preventing infections before they become severe, including GBS, RSV, and pneumococcal disease.
- Maternal immunization to protect newborns from early-life infection
- Infant and toddler vaccine studies assessing safety and immune response
- Prevention of serious respiratory and bacterial disease in early childhood
By studying both maternal and pediatric vaccination, the site supports strategies that aim to protect children from the earliest stages of life.
Neurologic and Long-Term Health Research
Among the broader portfolio, the site includes work related to nervous system diseases, with research exploring whether vaccination may influence the risk of incident dementia. This type of study looks beyond infection prevention and examines possible longer-term health benefits of immunization.
- Vaccine-related research connected to dementia risk reduction
- Health outcome studies in older adults
- Assessment of broader benefits of preventive vaccination
This adds a distinct public health dimension to the site’s vaccine portfolio, linking infectious disease prevention with aging and brain health.
Global Vaccine Development and Immune Response Testing
Across its trial portfolio, Rokotetutkimuskeskus Finvac Oy supports a wide range of vaccine development programs that compare immune responses, evaluate safety, and measure how well candidate vaccines prevent disease. The research spans multiple pathogens, from yellow fever to cytomegalovirus (CMV), showing a broad commitment to preventive medicine.
- Evaluation of candidate vaccines against viral and bacterial infections
- Measurement of antibody responses and protection after vaccination
- Studies designed to improve prevention in both healthy and at-risk populations
Overall, the site serves as an active clinical research center for testing new immunization strategies and improving protection against important infectious diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 therapeutic areas and 15 of 103 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 102 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Pfizer Inc.2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GlaxoSmithKline Biologicals6trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 107 other sites in Finland
Therapeutic Area Benchmark — Finland
Select a therapeutic area to compare against other sites in Finland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Finland
Market Share
Country: Finland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rokotetutkimuskeskus Finvac Oy
lock Showing 1 of 25 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Healthy Pre-Term and Full-Term Infants | Merck Sharp & Dohme LLC | Phase IV | Not Recruiting | Nov 2022 | Feb 2024 |
IMP list
lock Showing 1 of 103 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| A/Victoria/4897/2022 (H1N1)Pdm09-Like Strain (A/Victoria/4897/2022, Ivr-238) | 3 | Unknown | 2023-10-20 | 2025-10-20 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.